Clinical Trial Update: A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH [Phase 3]

View source ↗

Summary

GlaxoSmithKline is conducting a Phase 3 pivotal trial to evaluate Efimosfermin Alfa in participants with biopsy-confirmed F2- or F3-stage MASH, within non-alcoh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Efimosfermin Alfa (efimosfermin alfa)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Non-alcoholic Fatty Liver Disease | Phase 3 | Status: RECRUITING